WO2003059381A3 - Immunogenic preparations and vaccines on the basis of mrna - Google Patents

Immunogenic preparations and vaccines on the basis of mrna Download PDF

Info

Publication number
WO2003059381A3
WO2003059381A3 PCT/EP2003/000497 EP0300497W WO03059381A3 WO 2003059381 A3 WO2003059381 A3 WO 2003059381A3 EP 0300497 W EP0300497 W EP 0300497W WO 03059381 A3 WO03059381 A3 WO 03059381A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
mrna
basis
immunogenic preparations
immunogenic
Prior art date
Application number
PCT/EP2003/000497
Other languages
French (fr)
Other versions
WO2003059381A2 (en
Inventor
Steve Cyril Pascolo
Ingmar Hoerr
Hans-Georg Rammensee
Der Muelbe Florian Von
Marie-Louise Michel
Hueseyin Firat
Francois Albert Lemonnier
Original Assignee
Curevac Gmbh
Pasteur Institut
Inst Nat Sante Rech Med
Genethon Iii
Steve Cyril Pascolo
Ingmar Hoerr
Hans-Georg Rammensee
Der Muelbe Florian Von
Marie-Louise Michel
Hueseyin Firat
Francois Albert Lemonnier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10201732A external-priority patent/DE10201732A1/en
Priority claimed from FR0212894A external-priority patent/FR2845918A1/en
Application filed by Curevac Gmbh, Pasteur Institut, Inst Nat Sante Rech Med, Genethon Iii, Steve Cyril Pascolo, Ingmar Hoerr, Hans-Georg Rammensee, Der Muelbe Florian Von, Marie-Louise Michel, Hueseyin Firat, Francois Albert Lemonnier filed Critical Curevac Gmbh
Priority to AU2003235707A priority Critical patent/AU2003235707A1/en
Publication of WO2003059381A2 publication Critical patent/WO2003059381A2/en
Publication of WO2003059381A3 publication Critical patent/WO2003059381A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to the field of vaccination and immune stimulation by the use of nucleic acids, in particular RNA, coding for one or more antigens of pathogenic micro organisms.
PCT/EP2003/000497 2002-01-18 2003-01-20 Immunogenic preparations and vaccines on the basis of mrna WO2003059381A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003235707A AU2003235707A1 (en) 2002-01-18 2003-01-20 Immunogenic preparations and vaccines on the basis of mrna

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10201732A DE10201732A1 (en) 2002-01-18 2002-01-18 New immunogenic preparation, useful for preparing a composition for treating or preventing infections caused by HIV, Hepatitis B or C virus, Rous-Sarcoma virus or Chlamydia pneumoniae
DE10201732.8 2002-01-18
FR0212894 2002-10-16
FR0212894A FR2845918A1 (en) 2002-10-16 2002-10-16 New immunogenic preparation, useful for preparing a composition for treating or preventing infections caused by HIV, Hepatitis B or C virus, Rous-Sarcoma virus or Chlamydia pneumoniae

Publications (2)

Publication Number Publication Date
WO2003059381A2 WO2003059381A2 (en) 2003-07-24
WO2003059381A3 true WO2003059381A3 (en) 2004-01-22

Family

ID=26010937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000497 WO2003059381A2 (en) 2002-01-18 2003-01-20 Immunogenic preparations and vaccines on the basis of mrna

Country Status (2)

Country Link
AU (1) AU2003235707A1 (en)
WO (1) WO2003059381A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
JP7278677B2 (en) 2015-10-22 2023-05-22 モデルナティエックス インコーポレイテッド human cytomegalovirus vaccine
US11965000B2 (en) 2023-09-07 2024-04-23 CureVac SE Respiratory syncytial virus (RSV) vaccine

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392341B1 (en) 2001-06-05 2005-03-30 Curevac GmbH Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
DK1519714T3 (en) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Method and apparatus for preparing liposomes
DE10335833A1 (en) * 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE102004035227A1 (en) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA mixture for vaccination against tumor diseases
JP2010507361A (en) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
HUE025027T2 (en) 2008-01-31 2016-07-28 Curevac Gmbh NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
BR112013002298A2 (en) 2010-07-30 2016-05-24 Curevac Gmbh nucleic acid complexation with disulfide crosslinked cationic components for transfection and immune stimulation.
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
EP3138577A1 (en) 2011-03-02 2017-03-08 CureVac AG Vaccination in elderly patients
DK2714071T3 (en) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh INDIVIDUALIZED VACCINES AGAINST CANCER
PL2714071T3 (en) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20160044566A (en) 2013-08-21 2016-04-25 큐어백 아게 Respiratory syncytial virus (RSV) vaccine
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3129050A2 (en) 2014-04-01 2017-02-15 CureVac AG Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
EP3708668B1 (en) 2014-12-12 2022-07-27 CureVac AG Artificial nucleic acid molecules for improved protein expression
SG10201907164SA (en) 2015-04-22 2019-09-27 Curevac Ag Rna containing composition for treatment of tumor diseases
DK3294885T3 (en) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh METHOD OF PREPARING RNA
DE22190069T1 (en) 2015-05-29 2023-03-02 Curevac Real Estate Gmbh PROCESS FOR RNA PREPARATION AND PURIFICATION WITH AT LEAST ONE TANGENTIAL FLOW FILTRATION STEP
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. Human cytomegalovirus vaccine
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
UY37621A (en) 2017-02-28 2018-09-28 Sanofi Sa THERAPEUTIC ARN THAT CODIFIES CYTOKINS
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO1999014346A2 (en) * 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY
WO1999020774A2 (en) * 1997-10-20 1999-04-29 Genzyme Transgenics Corporation NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
EP1083232A1 (en) * 1999-09-09 2001-03-14 Jung, Günther, Prof. Dr. Transfer of mRNA using polycationic compounds
WO2001021810A1 (en) * 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002085434A1 (en) * 2001-04-21 2002-10-31 Curevac Gmbh Injection device for administering rna
WO2002098443A2 (en) * 2001-06-05 2002-12-12 Curevac Gmbh Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1998034640A2 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO1999014346A2 (en) * 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY
WO1999020774A2 (en) * 1997-10-20 1999-04-29 Genzyme Transgenics Corporation NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
EP1083232A1 (en) * 1999-09-09 2001-03-14 Jung, Günther, Prof. Dr. Transfer of mRNA using polycationic compounds
WO2001021810A1 (en) * 1999-09-17 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002085434A1 (en) * 2001-04-21 2002-10-31 Curevac Gmbh Injection device for administering rna
WO2002098443A2 (en) * 2001-06-05 2002-12-12 Curevac Gmbh Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOCZKOWSKI D ET AL: "DENDRITIC CELLS PULSED WITH RNA ARE POTENT ANTIGEN-PRESENTING CELLSIN VITRO AND IN VIVO", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 184, no. 2, August 1996 (1996-08-01), pages 465 - 472, XP002921123, ISSN: 0022-1007 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1987, BENNETT D D ET AL: "IMMUNIZATION WITH ENVELOPE GLYCOPROTEIN OF AN AVIAN RNA TUMOR VIRUS PROTECTS AGAINST SARCOMA VIRUS TUMOR INDUCTION ROLE OF SUBGROUP", XP002252816, Database accession no. PREV198784121053 *
FIRAT HUSEYIN ET AL: "Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 10, October 2001 (2001-10-01), pages 3064 - 3074, XP002252815, ISSN: 0014-2980 *
HOERR INGMAR ET AL: "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 30, no. 1, January 2000 (2000-01-01), pages 1 - 7, XP002243972, ISSN: 0014-2980 *
HOLCIK MARTIN ET AL: "Four highly stable eukaryotic mRNAs assemble 3' untranslated region RNA-protein complexes sharing cis and trans components.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 6, 1997, 1997, pages 2410 - 2414, XP002243974, ISSN: 0027-8424 *
LOIRAT D ET AL: "Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 OCT 2000, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4748 - 4755, XP002243973, ISSN: 0022-1767 *
SVANHOLM ET AL: "Protective DNA Immunization against Chlamydia pneumoniae", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 51, no. 4, April 2000 (2000-04-01), pages 345 - 353, XP002191683, ISSN: 0300-9475 *
VIRUS RESEARCH, vol. 8, no. 1, 1987, pages 73 - 77, ISSN: 0168-1702 *
WOODBERRY T ET AL: "Immunogenicity of a human immunodeficiency virus (HIV) polytope vacine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 7, July 1999 (1999-07-01), pages 5320 - 5325, XP002162348, ISSN: 0022-538X *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
JP7278677B2 (en) 2015-10-22 2023-05-22 モデルナティエックス インコーポレイテッド human cytomegalovirus vaccine
US11965000B2 (en) 2023-09-07 2024-04-23 CureVac SE Respiratory syncytial virus (RSV) vaccine

Also Published As

Publication number Publication date
AU2003235707A8 (en) 2003-07-30
WO2003059381A2 (en) 2003-07-24
AU2003235707A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2004075829A3 (en) Adjuvanted influenza vaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
PT1487485E (en) Imidazoquinoline adjuvants for dna vaccines
WO2003028656A3 (en) Adjuvant compositions
WO1999041369A3 (en) Genetic vaccine vector engineering
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2000056360A3 (en) Vaccine against antigens from bacteriae
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2004030608A3 (en) Nanoemulsion vaccines
WO2003002065A3 (en) Hcv e1e2 vaccine compositions
WO2002087494A3 (en) Novel vaccine
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2005007673A3 (en) Immunogenic peptides
WO2002019968A3 (en) Genetically engineered co-expression dna vaccines, construction methods and uses thereof
WO2004032860A3 (en) Hiv vaccine formulations
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
AU2002326961A1 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2005033265A3 (en) Optimized multi-epitope constructs and uses thereof
HK1082666A1 (en) Ihnv g fusion protein for immune stimulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP